In this issue:
KRAS mutation burden and treatment response
Cetuximab adds no benefit to FLOX
Age and comorbidities do not affect oxaliplatin outcomes
Capecitabine can substitute for 5-FU
Celecoxib reduces capecitabine-induced HFS
Neoadjuvant response correlated to oncol
Please login below to download this issue (PDF)